Patents by Inventor Shuji Hinuma
Shuji Hinuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7972800Abstract: By using a G protein-coupled receptor protein comprising an amino acid sequence, which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and an ionizable metal element or a salt thereof, an agonist for or an antagonist to the above receptor protein or a salt thereof can be efficiently screened.Type: GrantFiled: April 23, 2009Date of Patent: July 5, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuaki Ito, Ryo Fujii, Makoto Kobayashi, Shuji Hinuma, Tadatoshi Hashimoto, Yasuhiro Tanaka
-
Patent number: 7960369Abstract: The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.Type: GrantFiled: November 6, 2003Date of Patent: June 14, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Kohji Fukatsu, Shinobu Sasaki, Shuji Hinuma, Yasuaki Ito, Nobuhiro Suzuki, Masataka Harada, Tsuneo Yasuma
-
Patent number: 7943137Abstract: By using FPRL1 ligand, which comprises the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 17 or SEQ ID NO: 21, and FPRL1, an efficient screening for FPRL1 agonist or FPRL1 antagonist can be performed.Type: GrantFiled: November 6, 2003Date of Patent: May 17, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Shuji Hinuma, Makoto Kobayashi, Yugo Habata, Masataka Harada, Shoichi Ohkubo, Hiromi Yoshida, Kazunori Nishi
-
Patent number: 7927821Abstract: The present invention provides a method of screening an agonist or antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or a salt thereof and the ligand or a salt thereof; etc. The present invention is useful for screening agents for the prevention/treatment of, e.g., leukopenia, leukemia, lymphoma, malignant tumor, ulcerative colitis, rheumatoid arthritis, inflammatory bowel disorders, tonsil disorders, collagen disease, inflammatory disease, leukocytosis, heart failure, inherited muscle disorders, muscular dystrophy, neuromuscular degenerative disease, myocardial infarction, obesity, mellitus diabetes, hyperlipemia, arteriosclerosis, metabolic syndrome, thrombocytopenia, thrombocytosis, cancer, pulmonary edema, multiple organ failure, etc.Type: GrantFiled: April 11, 2005Date of Patent: April 19, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Ryo Fujii, Shoichi Okubo, Kazunori Nishi, Shuji Hinuma, Masaaki Mori
-
Patent number: 7833722Abstract: The present invention provides a method of screening an agonist/antagonist of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or its salt and a ligand or its salt; and so on. The screening method of the present invention is useful for screening an agent for the prevention/treatment of nervous system diseases or neuropathic pains.Type: GrantFiled: April 26, 2005Date of Patent: November 16, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Ryo Fujii, Masataka Harada, Shuji Hinuma
-
Patent number: 7799533Abstract: This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.Type: GrantFiled: July 2, 2008Date of Patent: September 21, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Shuji Hinuma, Kazuhiko Tatemoto, Masaki Hosoya, Yugo Habata, Ryo Fujii, Chieko Kitada
-
Patent number: 7662574Abstract: The polypeptides in the present invention possess the effects of promoting and inhibiting the secretion of prolactin, and are thus useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion stimulants, which are associated with the secretion of prolactin, such as hypoovarianism, spermatic underdevelopment, menopausal symptoms, hypothyroidism, etc. The polypeptides are useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion inhibitors, which are associated with the secretion of prolactin, such as pituitary tumor, diencephalon tumor, menstrual disorder, autoimmune diseases, prolactinoma, sterility, impotence, amenorrhea, lactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castilo syndrome, Forbes-Albright syndrome, lymphoma, Sheehan's syndrome, spermatogenesis disorder, etc.Type: GrantFiled: February 2, 2007Date of Patent: February 16, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Takuya Watanabe, Kuniko Kikuchi, Yasuko Terao, Yasushi Shintani, Shuji Hinuma, Shoji Fukusumi, Ryo Fujii, Masaki Hosoya, Chieko Kitada
-
Patent number: 7635751Abstract: The present invention relates to novel peptide derivatives, which are recognized as ligands to G-coupled protein receptor proteins. The peptide of the present invention can be used in (1) development of a receptor binding assay system using the expression system of the recombinant receptor protein and screening of candidates for pharmaceutical compounds, and (2) development of pharmaceutical preparations such as a neutral nerve function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive organ function regulator, a metabolic function regulator, a generative organ regulator or the like.Type: GrantFiled: March 22, 2001Date of Patent: December 22, 2009Assignee: Takada Pharmaceutical Company LimitedInventors: Chieko Kitada, Naoki Nishizawa, Shuji Hinuma, Masaki Hosoya
-
Patent number: 7625887Abstract: It is intended to provide a TGR5 receptor agonist containing a fused ring compound represented by the following general formula, its salt or a prodrug thereof: (1) wherein ring A represents an optionally substituted aromatic ring; and the ring B? represents a 5- to 8-membered ring having one or more substituents; which is useful in treating various diseases.Type: GrantFiled: January 27, 2004Date of Patent: December 1, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Yuji Kawamata, Taisuke Tawaraishi, Yuji Ishichi, Mariko Hirohashi
-
Patent number: 7598351Abstract: The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.Type: GrantFiled: December 3, 2004Date of Patent: October 6, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
-
Publication number: 20090239839Abstract: An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.Type: ApplicationFiled: February 24, 2009Publication date: September 24, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Fumio ITOH, Shuji Hinuma, Naoyuki Kanzaki, Hiroshi Mabuchi, Hiromi Yoshida, Hirokazu Matsumoto, Takeshi Wakabayashi
-
Publication number: 20090232771Abstract: The present invention provides methods of screening genes associated with cell regeneration, growth and differentiation and regulators for cell regeneration, growth or differentiation; regulators for cell regeneration, growth or differentiation; and so on.Type: ApplicationFiled: July 12, 2005Publication date: September 17, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Shuji Hinuma, Masaki Hosoya, Rie Kunisada
-
Publication number: 20090227037Abstract: By using a G protein-coupled receptor protein comprising an amino acid sequence, which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and an ionizable metal element or a salt thereof, an agonist for or an antagonist to the above receptor protein or a salt thereof can be efficiently screened.Type: ApplicationFiled: April 23, 2009Publication date: September 10, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yasuaki ITO, Ryo Fuji, Makoto Kobayashi, Shuji Hinuma, Tadatoshi Hashimoto, Yasuhiro Tanaka
-
Patent number: 7517661Abstract: The use of a G-protein coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof and a ligand peptide comprising the amino acid sequence represented by any of SEQ ID NO: 3 to 7, or a salt thereof, enables efficient screening of an agonist or antagonist for the above receptor protein or a salt thereof.Type: GrantFiled: April 22, 2004Date of Patent: April 14, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Makoto Kobayashi, Yugo Habata, Ryo Fujii, Shuji Hinuma
-
Publication number: 20090075334Abstract: This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.Type: ApplicationFiled: July 2, 2008Publication date: March 19, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Shuji Hinuma, Kazuhiko Tatemoto, Masaki Hosoya, Yugo Habata, Ryo Fujii, Chieko Kitada
-
Publication number: 20090012093Abstract: The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.Type: ApplicationFiled: November 6, 2003Publication date: January 8, 2009Inventors: Kohji Fukatsu, Shinobu Sasaki, Shuji Hinuma, Yasuaki Ito, Nobuhiro Suzuki, Masataka Harada, Tsuneo Yasuma
-
Publication number: 20080305110Abstract: The present invention provides a method of screening an agonist or antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or a salt thereof and the ligand or a salt thereof; etc. The present invention is useful for screening agents for the prevention/treatment of, e.g., leukopenia, leukemia, lymphoma, malignant tumor, ulcerative colitis, rheumatoid arthritis, inflammatory bowel disorders, tonsil disorders, collagen disease, inflammatory disease, leukocytosis, heart failure, inherited muscle disorders, muscular dystrophy, neuromuscular degenerative disease, myocardial infarction, obesity, mellitus diabetes, hyperlipemia, arteriosclerosis, metabolic syndrome, thrombocytopenia, thrombocytosis, cancer, pulmonary edema, multiple organ failure, etc.Type: ApplicationFiled: April 11, 2005Publication date: December 11, 2008Applicant: Takeda Pharmaceutical Company LimitedInventors: Ryo Fujii, Shoichi Okubo, Kazunori Nishi, Shuji Hinuma, Masaaki Mori
-
Publication number: 20080248041Abstract: The present invention provides a method of screening an agonist/antagonist of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or its salt and a ligand or its salt; and so on. The screening method of the present invention is useful for screening an agent for the prevention/treatment of nervous system diseases or neuropathic pains.Type: ApplicationFiled: April 26, 2005Publication date: October 9, 2008Applicant: Takeda Pharmaceutical Company LimitedInventors: Ryo Fujii, Masataka Harada, Shuji Hinuma
-
Patent number: 7410776Abstract: This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.Type: GrantFiled: June 27, 2002Date of Patent: August 12, 2008Assignee: Takeda Pharmaceutical Company LimitedInventors: Shuji Hinuma, Kazuhiko Tatemoto, Masaki Hosoya, Yugo Habata, Ryo Fujii, Chieko Kitada
-
Publication number: 20080160033Abstract: By using a G protein-coupled receptor protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 8, or a salt thereof, and a fatty acid, a compound or its salt that changes the binding property of the receptor protein or a salt thereof to the fatty acid can be efficiently screened.Type: ApplicationFiled: January 15, 2004Publication date: July 3, 2008Inventors: Yasuaki Ito, Ryo Fujii, Shuji Hinuma, Shoji Fukusumi, Minoru Maruyama